126
Views
5
CrossRef citations to date
0
Altmetric
Research Articles

The pH-triggered polyglutamate brush co-delivery of MDR1 and survivin-targeting siRNAs efficiently overcomes multi-drug resistance of NSCLC

, , , , , & show all
Pages 1862-1872 | Received 18 Jun 2020, Accepted 07 Sep 2020, Published online: 21 Sep 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Zhongjuan Wang, Shaobin Xu, Hongying Xia, Yanqiu Liu, Bin Li, Yueqin Liang & Zhongkun Li. (2022) A cationic cyclodextrin derivative-lipid hybrid nanoparticles for gene delivery effectively promotes stability and transfection efficiency. Drug Development and Industrial Pharmacy 48:1, pages 1-11.
Read now

Articles from other publishers (4)

Beinuo Wang, Ruijie Zhang, Yao Wang, Hang Qian, Di Wu, Binfeng He & Hu Liao. (2023) Targeting Rab26 to Conquer Cisplatin-Resistant Lung Cancer with Self-Assembled DNA Nanomaterials. Biomacromolecules 24:5, pages 2063-2074.
Crossref
Ying Meng, Rilan Bai & Jiuwei Cui. (2023) Precision targeted therapy for EGFR mutation‐positive NSCLC : Dilemmas and coping strategies . Thoracic Cancer 14:13, pages 1121-1134.
Crossref
Ganeshlenin Kandasamy & Dipak Maity. (2023) Current advancements in self-assembling nanocarriers-based siRNA delivery for cancer therapy. Colloids and Surfaces B: Biointerfaces 221, pages 113002.
Crossref
Parvez Khan, Jawed Akhtar Siddiqui, Imayavaramban Lakshmanan, Apar Kishor Ganti, Ravi Salgia, Maneesh Jain, Surinder Kumar Batra & Mohd Wasim Nasser. (2021) RNA-based therapies: A cog in the wheel of lung cancer defense. Molecular Cancer 20:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.